MDMA Statement on House Legislation Including an Additional 5-Year Suspension of the Medical Device Tax  ...

MDMA Statement on FDA’s Plan to Modernize the 510(k) Regulatory Pathway for Medical Devices  ...

MDMA Statement on FDA’s Updates to the “ Medical Device Safety Action Plan”   Washingto...

MDMA Statement on the ICIJ Coverage of Medical Devices   Washington, D.C.  – Mark Leahe...

MDMA Statement on the Enactment of the  “SUPPORT for Patients and Communities Act”   Wash...

MDMA Statement on Senate Passage of the “Opioid Crisis Response Act of 2018”   Washington, D.C. &nbs...

MDMA   Statement on Committee Passage of the “Local Coverage Determination Clarification Act of 2017” &...

MDMA Statement on House Passage of a Full Repeal of the Medical Device Tax Washington, D.C....

  MDMA Statement on CMMI Director Boehler’s Selection as  Senior Advisor to HHS Secretary Azar...

MDMA Submits Comments to USPTO to Strengthen MedTech Property Rights MDMA urged the U.S. Patent and Trademark Off...

USTR Publishes Updated List of Import Tariffs The USTR published its' final Section 301 list of 25% import ta...

MDMA Statement on FDA’s “ Medical Device Safety Action Plan”   Washington, D.C.  – Mark Leah...

MDMA Statement on the “STRONGER Patents Act” Washington, D.C.  – Mark Leahey, President and CEO of the...

MDMA Response to President Trump’s State of the Union Address   Washington, D.C....

MDMA Statement on Alex Azar’s Confirmation as HHS Secretary WASHINGTON, DC  -- Mark Leahey, President an...

MDMA Statement on an Additional Two-Year Suspension of the Device Tax Washington, D.C.  – Mark...

MDMA Statement on House Legislation to Extend the Medical Device Tax Suspension for Two Years Washington, D.C. &...

MDMA Statement on the Introduction of a 5-Year Suspension of the Medical Device Tax   Washington,...

MDMA Survey Highlights the Damage Device Tax Reinstatement Would Have on R&D, Jobs and Expansion Plans...

MDMA Statement on Tax Reform Blueprint WASHINGTON, DC  -   MDMA President and CEO Mark Leahey issued...

MDMA   Applauds Senate Passage of the Medical Device User Fee Agreement WASHINGTON, DC  -   M...

MDMA Statement on House Passage of the Medical Device User Fee Agreement   WASHINGTON, DC &n...

MDMA Statement on the “STRONGER Patents Act” Washington, D.C.   – Mark Leahey, President and CEO of t...

MDMA  Statement  on Scott  Gottlieb ’s Confirmation as the Next FDA Commissioner  ...

MDMA Board Member Testifies Before House Committee Examining Medical Device User Fees   WASHI...

MDMA Statement on HELP Committee Hearing on User Fees WASHINGTON, DC   – Mark Leahey,...

MDMA Statement on Seema Verma’s Confirmation as the Next CMS Administrator   WASHINGTON, DC – Mark Le...

MDMA Statement on the Nomination of Scott Gottlieb to Lead the FDA WASHINGTON, DC   -- Mark Leah...

MDMA Response to President Trump’s Address to Congress WASHINGTON, DC – Mark Leahey, President and CEO of...

MDMA Statement on Dr. Price’s Confirmation as HHS Secretary WASHINGTON, DC  -- Mark Leahey, Presid...

  MDMA Survey Shows Device Tax Suspension Creating Jobs, Increasing R&D Te...

MDMA Statement on House Passage of the Updated “21st Century Cures Act”   WASHI...

MDMA Statement on President-elect Trump's Nomination for HHS Secretary WASHINGTON, DC  -- Mark Leahey,...

FDA Issues Draft Guidance on Medical Device Software The Food and Drug Administration (FDA) issued draft guidance t...

MDMA Submits Comments to CMS on Proposed Changes to Comprehensive Care for Joint Replacement Model MDMA submitted...